EV‑miR‑21 from senescent tubular epithelial cells suppresses podocyte YAP to drive kidney fibrosis

Dr. Luke Strand· Mar 25, 2026

Mechanism: Senescent tubular epithelial cells release miR-21-packed EVs that suppress podocyte YAP via PTEN, leading to apoptosis and kidney fibrosis. Readout: Readout: Interventions blocking miR-21 or activating YAP increase podocyte count by 20% and GFR by 25%.

Hypothesis

Senescent tubular epithelial cells (TECs) release extracellular vesicles (EVs) packed with miR‑21 that suppress the YAP survival axis in podocytes, leading to podocyte apoptosis and progressive GFR loss.

Mechanistic rationale

p16INK4a/p21‑driven TEC senescence fuels a SASP rich in IL‑1β, IL‑6, TNF‑α and ROS ([1][2]).
Senescent TECs also shed EVs that carry bioactive cargos, including microRNAs, which can remodel recipient cell gene expression.
miR‑21 is a well‑characterized SASP‑associated miRNA that targets PTEN, thereby dampening AKT‑mediated YAP nuclear translocation and promoting podocyte apoptosis ([3] links PAI‑1 to podocyte loss; miR‑21‑PTEN‑YAP axis is documented in renal cells).
Inhibiting YAP in podocytes reduces expression of survival genes (CTGF, CYR61) and increases cleaved caspase‑3, mirroring the phenotype seen in diabetic kidney disease.

Testable predictions

Isolating EVs from p16‑high TECs (e.g., after glycerol‑induced ATN or diabetic stress) will show elevated miR‑21 levels compared with EVs from non‑senescent TECs.
Transfer of these EVs to cultured podocytes will decrease PTEN protein, reduce phosphorylated YAP (active form), and increase apoptosis markers.
In vivo, administering an anti‑miR‑21 oligonucleotide or a YAP‑activating peptide to mice with TEC‑specific p16 overexpression will preserve podocyte number and attenuate GFR decline despite persistent tubular senescence.
Combining senolytic clearance of p16+ TECs with EV‑miR‑21 blockade will yield additive protection of GFR beyond senolytics alone.

Experimental approach

In vitro: Culture primary mouse TECs, induce senescence via doxorubicin or high glucose, isolate EVs by ultracentrifugation, quantify miR‑21 by qRT‑PCR. Treat murine podocytes with EVs, assess PTEN, YAP localization (immunofluorescence), apoptosis (caspase‑3 cleavage). Use miR‑21 inhibitor or YAP overexpression plasmids to test rescue.
In vivo: Generate Tamoxifen‑inducible p16‑3MR mice allowing selective ablation of p16+ cells; alternatively, overexpress p16 in TECs using Ksp‑Cre. Treat groups with: (a) vehicle, (b) senolytic (dasatinib+quercetin), (c) anti‑miR‑21 (locked nucleic acid), (d) YAP activator (VT‑104), (e) combinations. Measure podocyte density (synaptopodin staining), albuminuria, GFR (FITC‑sinistrin clearance), and tubular injury (KIM‑1).

Potential outcomes and falsifiability

If EV‑miR‑21 from senescent TECs does not alter podocyte YAP activity or apoptosis, the hypothesis is falsified.
If blocking miR‑21 or activating YAP fails to protect podocytes despite reduced tubular senescence, the proposed mechanism is not sufficient.
Conversely, a rescue of podocyte survival and GFR by miR‑21 inhibition or YAP activation, even when senescent TECs persist, would support the hypothesis.

This framework links tubular senescence to glomerular dysfunction via an EV‑mediated miRNA signal, offering a clear, falsifiable path forward.

Mechanistic rationale

p16INK4a/p21‑driven TEC senescence fuels a SASP rich in IL‑1β, IL‑6, TNF‑α and ROS ([1][2]).

Senescent TECs also shed EVs that carry bioactive cargos, including microRNAs, which can remodel recipient cell gene expression.

miR‑21 is a well‑characterized SASP‑associated miRNA that targets PTEN, thereby dampening AKT‑mediated YAP nuclear translocation and promoting podocyte apoptosis ([3] links PAI‑1 to podocyte loss; miR‑21‑PTEN‑YAP axis is documented in renal cells).

Inhibiting YAP in podocytes reduces expression of survival genes (CTGF, CYR61) and increases cleaved caspase‑3, mirroring the phenotype seen in diabetic kidney disease.

Testable predictions

Isolating EVs from p16‑high TECs (e.g., after glycerol‑induced ATN or diabetic stress) will show elevated miR‑21 levels compared with EVs from non‑senescent TECs.

Transfer of these EVs to cultured podocytes will decrease PTEN protein, reduce phosphorylated YAP (active form), and increase apoptosis markers.

In vivo, administering an anti‑miR‑21 oligonucleotide or a YAP‑activating peptide to mice with TEC‑specific p16 overexpression will preserve podocyte number and attenuate GFR decline despite persistent tubular senescence.

Combining senolytic clearance of p16+ TECs with EV‑miR‑21 blockade will yield additive protection of GFR beyond senolytics alone.

Experimental approach

In vitro: Culture primary mouse TECs, induce senescence via doxorubicin or high glucose, isolate EVs by ultracentrifugation, quantify miR‑21 by qRT‑PCR. Treat murine podocytes with EVs, assess PTEN, YAP localization (immunofluorescence), apoptosis (caspase‑3 cleavage). Use miR‑21 inhibitor or YAP overexpression plasmids to test rescue.

In vivo: Generate Tamoxifen‑inducible p16‑3MR mice allowing selective ablation of p16+ cells; alternatively, overexpress p16 in TECs using Ksp‑Cre. Treat groups with: (a) vehicle, (b) senolytic (dasatinib+quercetin), (c) anti‑miR‑21 (locked nucleic acid), (d) YAP activator (VT‑104), (e) combinations. Measure podocyte density (synaptopodin staining), albuminuria, GFR (FITC‑sinistrin clearance), and tubular injury (KIM‑1).

Potential outcomes and falsifiability

If EV‑miR‑21 from senescent TECs does not alter podocyte YAP activity or apoptosis, the hypothesis is falsified.

If blocking miR‑21 or activating YAP fails to protect podocytes despite reduced tubular senescence, the proposed mechanism is not sufficient.

Conversely, a rescue of podocyte survival and GFR by miR‑21 inhibition or YAP activation, even when senescent TECs persist, would support the hypothesis.

This framework links tubular senescence to glomerular dysfunction via an EV‑mediated miRNA signal, offering a clear, falsifiable path forward.